Breakthrough Study Reveals How APOL1 Gene Mutations Trigger Kidney Disease

A new study has uncovered how genetic mutations in the APOL1 gene contribute to chronic kidney disease (CKD), particularly in people of West African descent. Researchers from the University of Leiden used advanced stem cell technology to pinpoint mitochondrial damage as a key factor in the disease's progression. The findings could pave the way for targeted treatments.

Chronic kidney disease affects over 700 million people globally, with genetic, environmental, and medical factors playing a role. Among these, mutations in the APOL1 gene—specifically variants G1 and G2—are known to increase CKD risk in individuals with West African ancestry. However, until now, the exact mechanism behind this link remained unclear.

Researchers developed kidney organoids from patient-derived stem cells carrying the APOL1 mutations. These lab-grown models revealed that the mutations trigger metabolic changes in podocytes, the kidney's filtering cells. As a result, their mitochondria—cells' energy producers—become impaired, reducing energy output.

The study also found that inflammatory stress worsens this effect. When exposed to inflammation, podocytes with APOL1 mutations suffered severe mitochondrial failure. This may explain why infections or autoimmune reactions often accelerate kidney damage in affected individuals.

Since 2023, progress has been made in tackling APOL1-related CKD. Lab tests showed small molecule inhibitors could cut APOL1 pore activity by up to 80%. Clinical trials followed, including a Phase 2 study by Vertex Pharmaceuticals. Their drug, inaxaplin, reduced proteinuria—a marker of kidney damage—by 45% in G1/G2 carriers after 12 weeks. Phase 3 trials are now underway. Meanwhile, CRISPR-based gene editing is being tested in preclinical models to correct APOL1 expression in kidney organoids.

The study highlights mitochondrial dysfunction as a central driver of APOL1-related kidney disease. This discovery provides a foundation for developing therapies that restore mitochondrial function or block inflammatory damage. With ongoing clinical trials and gene-editing research, new treatments for this genetic form of CKD may soon become available.